Ovarian Cancer Global Market Report 2025

The ovarian cancer market size has grown exponentially in recent years. It will grow from $3.67 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth during the historic period can be attributed to the rising elderly population, the increasing incidence of ovarian cancer cases, the growing prevalence of ovarian cancer, the expansion of government initiatives, and the rise in healthcare spending.

The ovarian cancer market size is expected to see exponential growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to increased research on targeted therapies and personalized medicine, a growing geriatric population, rising healthcare awareness, the increasing prevalence of ovarian cancer, and rising healthcare expenditures. Major trends in the forecast period include innovative therapies, advancements in radiation therapy, enhanced healthcare infrastructure, technological advancements, and the adoption of novel drugs.

The growing female population is anticipated to drive the expansion of the ovarian cancer market. The female population refers to the total number of females residing in a specific region or worldwide at a given time. This increase is influenced by factors such as higher life expectancy, improved healthcare, and demographic changes. Ovarian cancer treatments, including surgery, chemotherapy, targeted therapy, and immunotherapy, support the female population by removing cancerous cells, slowing disease progression, alleviating symptoms, and improving survival rates. These treatments ultimately enhance quality of life and provide hope for better long-term outcomes. For example, according to the Census Bureau, a US-based government agency, as of July 2022, the United States had an estimated female population of approximately 168 million, including about 1.9 million females aged 85 and older. Furthermore, a report published in December 2022 by CEIC Data, a UK-based financial services company, indicated that the number of females aged 15-64 reached 2,951,856 in 2022, up from 2,940,645 in 2021. As a result, the rising female population is contributing to the growth of the ovarian cancer market.

Companies in the ovarian cancer market are prioritizing advanced solutions, such as AI platforms, to enhance the accuracy of complex medical data analysis. An AI platform for ovarian cancer is a technology-driven system that utilizes artificial intelligence (AI) and machine learning (ML) to improve various aspects of ovarian cancer care. These platforms integrate medical imaging, genomic data, electronic health records (EHRs), and real-time analytics to support early detection, diagnosis, personalized treatment planning, and patient monitoring. For example, in February 2024, AIIMS Delhi, in collaboration with CDAC Pune, an India-based organization, introduced iOncology.ai, an AI-powered platform for the early detection of breast and ovarian cancer. This platform employs deep learning models to analyze radiological and histopathological images with high accuracy, aiming to improve early diagnosis and survival rates. Already implemented in multiple hospitals, iOncology.ai integrates with the healthcare system to provide risk assessments and recommend mammograms, particularly benefiting women in rural areas. This initiative is part of a broader effort to incorporate AI into healthcare and alleviate pressure on medical facilities.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. The acquisition aimed to enhance AbbVie's oncology portfolio by incorporating ImmunoGen's innovative antibody-drug conjugate, ELAHERE, alongside other promising cancer therapies. ImmunoGen Inc. is a US-based biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of ovarian cancer.

Major players in the ovarian cancer market are Pfizer Incorporated, Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Novogen Limited, Oasmia Pharmaceutical AB, Clovis Oncology Inc., Aeterna Zentaris Inc., Allarity Therapeutics Inc., Ellipses Pharma Ltd.

North America was the largest region in the ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs (ova) and hormones such as estrogen and progesterone. It can originate in different parts of the ovaries, including the surface epithelium, germ cells, or stroma.

The primary types of ovarian cancer include epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. Epithelial ovarian tumors arise from the epithelial cells that form the outer lining of the ovaries. Treatment options include chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. These treatments are administered through various routes, such as oral, parenteral, and other methods, and are utilized by different end-users, including hospitals, diagnostic centers, drug stores, online pharmacies, and others.

The ovarian cancer market research report is one of a series of new reports that provides ovarian cancer market statistics, including the ovarian cancer industry global market size, regional shares, competitors with the ovarian cancer market share, detailed ovarian cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the ovarian cancer industry. This ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ovarian cancer market consists of revenues earned by entities by providing services such as screening and early detection services, diagnostic imaging services, surgical treatment services, clinical trial services, and palliative and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer market also includes sales of taxane-based chemotherapy, surgical treatment devices, radiation therapy equipment, angiogenesis inhibitors, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.